Risk factors for the development of depression in patients with hepatitis C taking interferon- α
暂无分享,去创建一个
S. O'Mara | C. O’Farrelly | Kimberley J Smith | S. Norris | Kimberley J Smith | Suzanne Norris | Cliona O’Farrelly | Shane M O’Mara
[1] G. Foster,et al. Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection , 2010, Alimentary pharmacology & therapeutics.
[2] B. Pollock,et al. Labile Anger During Interferon Alfa Treatment is Associated With a Polymorphism in Tumor Necrosis Factor &agr; , 2010, Clinical neuropharmacology.
[3] Daniel J Buysse,et al. Poor sleep quality predicts onset of either major depression or subsyndromal depression with irritability during interferon-alpha treatment , 2010, Psychiatry Research.
[4] A. Miller,et al. Interferon-α effects on diurnal hypothalamic–pituitary–adrenal axis activity: relationship with proinflammatory cytokines and behavior , 2010, Molecular Psychiatry.
[5] C. Pariante,et al. Phospholipase A2 and Cyclooxygenase 2 Genes Influence the Risk of Interferon-α–Induced Depression by Regulating Polyunsaturated Fatty Acids Levels , 2010, Biological Psychiatry.
[6] R. Fontana,et al. A functional serotonin transporter gene polymorphism and depressive effects associated with interferon-alpha treatment. , 2010, Psychosomatics.
[7] S. Hamilton,et al. The genetics of major depression: moving beyond the monoamine hypothesis. , 2010, The Psychiatric clinics of North America.
[8] B. Morasco,et al. Neuroimmune mechanisms of cytokine-induced depression: Current theories and novel treatment strategies , 2010, Neurobiology of Disease.
[9] A. Hauschild,et al. Depressive Mood Changes and Psychiatric Symptoms During 12-month Low-dose Interferon-α Treatment in Patients With Malignant Melanoma: Results From the Multicenter DeCOG Trial , 2010, Journal of immunotherapy.
[10] S. Abbey,et al. A Review of Sleep Disturbance in Hepatitis C , 2010, Journal of clinical gastroenterology.
[11] F. Lotrich. Major depression during interferon-α treatment: vulnerability and prevention , 2009, Dialogues in Clinical Neuroscience.
[12] M. Hotopf,et al. Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-α and ribavirin treatment , 2009, Molecular Psychiatry.
[13] B. Pollock,et al. Cytokine-induced depression during IFN-α treatment: The role of IL-6 and sleep quality , 2009, Brain, Behavior, and Immunity.
[14] R. Dantzer,et al. CSF Concentrations of Brain Tryptophan and Kynurenines during Immune Stimulation with IFN-alpha: Relationship to CNS Immune Responses and Depression , 2009, Molecular Psychiatry.
[15] R. Fontana,et al. Prospective Analysis of Depression During Peginterferon and Ribavirin Therapy of Chronic Hepatitis C: Results of the Virahep-C Study , 2009, The American Journal of Gastroenterology.
[16] R. Navinés,et al. Pegylated interferon and ribavirin-induced depression in chronic hepatitis C: role of personality. , 2009, The Journal of clinical psychiatry.
[17] D. F. Drake,et al. Activation of Central Nervous System Inflammatory Pathways by Interferon-Alpha: Relationship to Monoamines and Depression , 2009, Biological Psychiatry.
[18] B. Pollock,et al. Risk for Depression During Interferon-Alpha Treatment Is Affected by the Serotonin Transporter Polymorphism , 2009, Biological Psychiatry.
[19] R. Fontana,et al. Changes in Mood States and Biomarkers During Peginterferon and Ribavirin Treatment of Chronic Hepatitis C , 2008, The American Journal of Gastroenterology.
[20] T. Harris,et al. Depression and the serotonin transporter 5-HTTLPR polymorphism: a review and a hypothesis concerning gene-environment interaction. , 2008, Journal of affective disorders.
[21] G. Pagnoni,et al. IFN-alpha-induced motor slowing is associated with increased depression and fatigue in patients with chronic hepatitis C , 2008, Brain, Behavior, and Immunity.
[22] M. J. van de Laar,et al. Surveillance and epidemiology of hepatitis B and C in Europe - a review. , 2008, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[23] N. Ozaki,et al. A link between stress and depression: Shifts in the balance between the kynurenine and serotonin pathways of tryptophan metabolism and the etiology and pathophysiology of depression , 2008, Stress.
[24] G. Foster,et al. Hepatitis C virus therapy to date , 2008, Antiviral therapy.
[25] M. Scheurlen,et al. Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study , 2007, Gut.
[26] H. Wittchen,et al. Methodological approaches in the assessment of interferon‐alfa‐induced depression in patients with chronic hepatitis C – a critical review , 2007, International journal of methods in psychiatric research.
[27] J. Russell,et al. Neurobiology of depression: an integrated view of key findings , 2007, International journal of clinical practice.
[28] M. Van Ranst,et al. Early prediction of major depression in chronic hepatitis C patients during peg-interferon alpha-2b treatment by assessment of vegetative-depressive symptoms after four weeks. , 2007, World journal of gastroenterology.
[29] M. Miquel,et al. De novo depression and anxiety disorders and influence on adherence during peginterferon‐alpha‐2a and ribavirin treatment in patients with hepatitis C , 2007, Alimentary pharmacology & therapeutics.
[30] P. Hauser,et al. A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C. , 2007, Journal of affective disorders.
[31] R. Bressan,et al. Incidence of psychiatric side effects during pegylated interferon‐ α retreatment in nonresponder hepatitis C virus‐infected patients , 2007, Liver international : official journal of the International Association for the Study of the Liver.
[32] B. Pollock,et al. Depression following pegylated interferon-alpha: characteristics and vulnerability. , 2007, Journal of psychosomatic research.
[33] B. Leonard. HPA and Immune Axes in Stress: Involvement of the Serotonergic System , 2007, Neuroimmunomodulation.
[34] R. Fontana,et al. Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C , 2007, Hepatology.
[35] J. Zajecka,et al. Paroxetine for prevention of depressive symptoms induced by interferon‐alpha and ribavirin for hepatitis C , 2007, Alimentary pharmacology & therapeutics.
[36] K. Lesch,et al. Serotonin-1A receptor gene HTR1A variation predicts interferon-induced depression in chronic hepatitis C. , 2007, Gastroenterology.
[37] M. Maj,et al. Subthreshold mania as predictor of depression during interferon treatment in HCV+ patients without current or lifetime psychiatric disorders. , 2007, Journal of psychosomatic research.
[38] N. Nicolson,et al. Interferon-alpha-induced depressive symptoms are related to changes in the cytokine network but not to cortisol. , 2007, Journal of psychosomatic research.
[39] V. de Lédinghen,et al. Impact on adherence and sustained virological response of psychiatric side effects during peginterferon and ribavirin therapy for chronic hepatitis C , 2006, Alimentary pharmacology & therapeutics.
[40] D. Levinson. The Genetics of Depression: A Review , 2006, Biological Psychiatry.
[41] M. Maes,et al. Baseline Immune Activation as a Risk Factor for the Onset of Depression During Interferon-Alpha Treatment , 2006, Biological Psychiatry.
[42] J. McHutchison,et al. Diagnosis and treatment of chronic hepatitis C infection , 2006, BMJ : British Medical Journal.
[43] R. De La Garza,et al. Interferon-Induced Depression in Chronic Hepatitis C: A Review of Its Prevalence, Risk Factors, Biology, and Treatment Approaches , 2006, Journal of clinical gastroenterology.
[44] Z. Younossi,et al. Depression, anemia and health-related quality of life in chronic hepatitis C. , 2006, Journal of hepatology.
[45] H. Anisman,et al. The pathogenesis of clinical depression: Stressor- and cytokine-induced alterations of neuroplasticity , 2005, Neuroscience.
[46] A. Dunn,et al. Cytokines as mediators of depression: What can we learn from animal studies? , 2005, Neuroscience & Biobehavioral Reviews.
[47] N. Dafny,et al. Interferon and the central nervous system. , 2005, European journal of pharmacology.
[48] J. Korf,et al. Irritability Rather Than Depression During Interferon Treatment Is Linked to Increased Tryptophan Catabolism , 2005, Psychosomatic medicine.
[49] Colin W Shepard,et al. Global epidemiology of hepatitis C virus infection. , 2005, The Lancet. Infectious diseases.
[50] R. Hashimoto,et al. The Gem interacting protein (GMIP) gene is associated with major depressive disorder , 2005, Neurogenetics.
[51] Andrew H. Miller,et al. Promoter Polymorphisms of the Interferon-α Receptor Gene and Development of Interferon-Induced Depressive Symptoms in Patients with Chronic Hepatitis C: Preliminary Findings , 2005, Neuropsychobiology.
[52] A. Meyer-Lindenberg,et al. 5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression , 2005, Nature Neuroscience.
[53] A. Heinz,et al. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. , 2005, Journal of hepatology.
[54] D. Duane. Increased risk for recurrent major depression in DYT1 dystonia mutation carriers , 2005, Neurology.
[55] M. Rizzetto,et al. Natural history of hepatitis C virus infection: from chronic hepatitis to cirrhosis, to hepatocellular carcinoma. , 2005, Minerva gastroenterologica e dietologica.
[56] H. Anisman,et al. Cytokines as a precipitant of depressive illness: animal and human studies. , 2005, Current pharmaceutical design.
[57] M. Wichers,et al. Cytokines and major depression , 2005, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[58] M. Rietschel,et al. The power of sample size and homogenous sampling: Association between the 5-HTTLPR serotonin transporter polymorphism and major depressive disorder , 2005, Biological Psychiatry.
[59] M. Hotopf,et al. Psychopathological symptoms during interferon-α and ribavirin treatment: effects on virologic response , 2005, Molecular Psychiatry.
[60] C. Nemeroff,et al. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. , 2005, The Journal of clinical psychiatry.
[61] Thomas Meitinger,et al. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment , 2004, Nature Genetics.
[62] P. Hauser,et al. The phenomenology and treatment of interferon-induced depression. , 2004, Journal of affective disorders.
[63] Z. Younossi,et al. Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia. , 2004, Cleveland Clinic journal of medicine.
[64] A. S. Elhwuegi. Central monoamines and their role in major depression , 2004, Progress in Neuro-psychopharmacology and Biological Psychiatry.
[65] R. Dantzer,et al. Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy , 2004, Brain, Behavior, and Immunity.
[66] B. Bacon. Managing hepatitis C. , 2004, The American journal of managed care.
[67] Luca Mascitelli,et al. Viral hepatitis C , 2004, The Lancet.
[68] C. Nemeroff,et al. Interferon-alpha–induced changes in tryptophan metabolism relationship to depression and paroxetine treatment , 2003, Biological Psychiatry.
[69] Gustavo Turecki,et al. Impaired Repression at a 5-Hydroxytryptamine 1A Receptor Gene Polymorphism Associated with Major Depression and Suicide , 2003, The Journal of Neuroscience.
[70] A. Caspi,et al. Influence of Life Stress on Depression: Moderation by a Polymorphism in the 5-HTT Gene , 2003, Science.
[71] C. Nemeroff,et al. Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. , 2003, The American journal of psychiatry.
[72] M. Scheurlen,et al. Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. , 2003, The Journal of clinical psychiatry.
[73] G. Davis,et al. Projecting future complications of chronic hepatitis C in the United States , 2003, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[74] P. Thuras,et al. A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. , 2003, Psychosomatics.
[75] H. Grunze,et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups , 2003, Hepatology.
[76] B. Gohier,et al. Hepatitis C, alpha interferon, anxiety and depression disorders: A prospective study of 71 patients , 2003, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.
[77] M. Maes,et al. Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. , 2002, Journal of affective disorders.
[78] D. Dhumeaux,et al. Incidence of interferon alfa–induced depression in patients with chronic hepatitis C , 2002, Hepatology.
[79] D. Revicki,et al. Relationship of health‐related quality of life to treatment adherence and sustained response in chronic hepatitis C patients , 2002, Hepatology.
[80] R. Dantzer,et al. Cytokine-induced sickness behaviour: mechanisms and implications , 2002, Trends in Neurosciences.
[81] M. Maes,et al. Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms , 2001, Psychiatry Research.
[82] M. Scheurlen,et al. Compliance with Therapy in Patients with Chronic Hepatitis C: Associations with Psychiatric Symptoms, Interpersonal Problems, and Mode of Acquisition , 2001, Digestive Diseases and Sciences.
[83] Kenneth Koury,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[84] B. van der Linden,et al. Psychiatric comorbidity among hepatitis C-positive patients. , 2001, Psychosomatics.
[85] Huy A. Nguyen,et al. Influence of psychiatric diagnoses on interferon-α treatment for chronic hepatitis C in a veteran population , 2001, American Journal of Gastroenterology.
[86] J. Eckman,et al. Activation of Vascular Endothelial Cell Adhesion Molecule Expression by Sickle Blood Cells , 2001, Pediatric pathology & molecular medicine.
[87] J. Reichen,et al. Peginterferon alfa-2a in patients with chronic hepatitis C. , 2000, The New England journal of medicine.
[88] B. Redman,et al. Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[89] M. Willenbring,et al. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review. , 2000, The American journal of psychiatry.
[90] Jensen,et al. Pretreatment symptoms and dosing regimen predict side‐effects of interferon therapy for hepatitis C , 2000, Journal of viral hepatitis.
[91] R. Mulder,et al. Interferon treatment is not associated with a worsening of psychiatric symptoms in patients with hepatitis C , 2000, Journal of gastroenterology and hepatology.
[92] H. Miyaoka,et al. Depression from interferon therapy in patients with hepatitis C. , 1999, The American journal of psychiatry.
[93] A. Ravaud,et al. Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state. , 1999, New England Journal of Medicine.
[94] J. Hoefs,et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.
[95] William M. Lee,et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.
[96] G. Stark,et al. How cells respond to interferons. , 1998, Annual review of biochemistry.
[97] R. Dantzer,et al. Molecular Basis of Sickness Behavior a , 1998, Annals of the New York Academy of Sciences.
[98] K. Fukunishi,et al. Burns in a suicide attempt related to psychiatric side effects of interferon. , 1998, Burns : journal of the International Society for Burn Injuries.
[99] S. Donnelly. Patient management strategies for interferon alfa-2b as adjuvant therapy of high-risk melanoma. , 1998, Oncology nursing forum.
[100] Mark E. Johnson,et al. Hepatitis C virus and depression in drug users , 1998, American Journal of Gastroenterology.
[101] M. Malaguarnera,et al. Interferon Alpha-Induced Depression in Chronic Hepatitis C Patients: Comparison between Different Types of Interferon Alpha , 1998, Neuropsychobiology.
[102] E. Schiff,et al. Response to higher doses of interferon alfa‐2b in patients with chronic hepatitis C: A randomized multicenter trial , 1996, Hepatology.
[103] T. Okanoue,et al. Side effects of high-dose interferon therapy for chronic hepatitis C. , 1996, Journal of hepatology.
[104] C. Nemeroff,et al. Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. , 1994, Clinical chemistry.
[105] W. Banks,et al. Murine tumor necrosis factor alpha is transported from blood to brain in the mouse , 1993, Journal of Neuroimmunology.
[106] P. Brust,et al. Peptides and blood-brain barrier transport. , 1993, Physiological reviews.
[107] A. Dunn. Endotoxin-induced activation of cerebral catecholamine and serotonin metabolism: comparison with interleukin-1. , 1992, The Journal of pharmacology and experimental therapeutics.
[108] B. Hart. Biological basis of the behavior of sick animals , 1988, Neuroscience & Biobehavioral Reviews.
[109] J. Hoofnagle,et al. Psychiatric complications of long-term interferon alfa therapy. , 1987, Archives of internal medicine.
[110] H. Steinbusch,et al. Depressive symptoms following interferon-α therapy: mediated by immune-induced reductions in brain-derived neurotrophic factor? , 2011, The international journal of neuropsychopharmacology.
[111] Hymie Anisman,et al. Cascading effects of stressors and inflammatory immune system activation: implications for major depressive disorder. , 2009, Journal of psychiatry & neuroscience : JPN.
[112] R. Dantzer,et al. From inflammation to sickness and depression: when the immune system subjugates the brain , 2008, Nature Reviews Neuroscience.
[113] S. Sauleda,et al. The changing epidemiology of hepatitis C virus infection in Europe. , 2008, Journal of hepatology.
[114] W. Yates,et al. Preventing relapse of major depression during interferon-alpha therapy for hepatitis C--A pilot study. , 2007, Digestive diseases and sciences.
[115] S. Sleijfer,et al. Interferon-alpha influences tryptophan metabolism without inducing psychiatric side effects. , 2007, Neuropsychobiology.
[116] C. Iino. High dose interferon treatment in chronic hepatitis , 2006 .
[117] Andrew H. Miller,et al. Cytokines sing the blues: inflammation and the pathogenesis of depression. , 2006, Trends in immunology.
[118] MichaelRKraus,et al. Psychiatric side effects of pegylated interferon alfa-2b as compared to conventional interferon alfa-2b in patients with chronic hepatitis C , 2005 .
[119] Andrew H. Miller,et al. Neuropsychiatric adverse effects of interferon-alpha: recognition and management. , 2005, CNS drugs.
[120] E. D. De Toni,et al. Mood, cognition and EEG changes during interferon alpha (alpha-IFN) treatment for chronic hepatitis C. , 2005, Journal of affective disorders.
[121] K. Kowdley. Hematologic side effects of interferon and ribavirin therapy. , 2005, Journal of clinical gastroenterology.
[122] Andrew H. Miller,et al. Cytokines and psychopathology: lessons from interferon-alpha. , 2004, Biological psychiatry.
[123] C. Pariante,et al. Psychopharmacological treatment of depression, anxiety, irritability and insomnia in patients receiving interferon-alpha: a prospective case series and a discussion of biological mechanisms. , 2004, Journal of psychopharmacology.
[124] Sergi Papiol,et al. Interleukin-1beta (IL-1beta) gene and increased risk for the depressive symptom-dimension in schizophrenia spectrum disorders. , 2004, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[125] R. Dantzer,et al. [Neuro-immune interactions in psychopathology with the example of interferon-alpha-induced depression]. , 2003, Journal de la Societe de biologie.
[126] N. Izumi,et al. Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study. , 2003, General hospital psychiatry.
[127] Y. Jeong,et al. Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection , 2003 .
[128] M. Scheurlen,et al. Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C. , 2002, Alimentary pharmacology & therapeutics.
[129] H. Meltzer,et al. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. , 2002, Journal of clinical psychopharmacology.
[130] H. Grunze,et al. Interferon alpha (IFNalpha) and psychiatric syndromes: a review. , 2002, Progress in neuro-psychopharmacology & biological psychiatry.
[131] R. Fontana,et al. Emotional distress during interferon-alpha-2B and ribavirin treatment of chronic hepatitis C. , 2002, Psychosomatics.
[132] C. Howell,et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C , 2002, Molecular Psychiatry.
[133] B. Charlton. The malaise theory of depression: major depressive disorder is sickness behavior and antidepressants are analgesic. , 2000, Medical hypotheses.
[134] oseph,et al. PEGINTERFERON ALFA-2a IN PATIENTS WITH CHRONIC HEPATITIS C AND CIRRHOSIS PEGINTERFERON ALFA-2a IN PATIENTS WITH CHRONIC HEPATITIS C AND CIRRHOSIS , 2000 .
[135] C. Pariante,et al. Treatment with interferon-alpha in patients with chronic hepatitis and mood or anxiety disorders. , 1999, Lancet.
[136] S. Maier,et al. Cytokines for psychologists: implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition. , 1998, Psychological review.
[137] W. Yates,et al. Hepatitis C and depression , 1998, Depression and anxiety.
[138] C. Hunt,et al. Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life. , 1997, Digestive diseases and sciences.
[139] H. Janssen,et al. Suicide associated with alfa-interferon therapy for chronic viral hepatitis. , 1994, Journal of hepatology.
[140] R. Esteban,et al. Epidemiology of hepatitis C virus infection. , 1993, Journal of hepatology.
[141] S. Iino. High dose interferon treatment in chronic hepatitis C. , 1993, Gut.
[142] D. Begley. Chapter 24: The interaction of some centrally active drugs with the blood-brain barrier and circumventricular organs , 1992 .